Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + vunakizumab first-line maintenance in extensive-stage small cell lung cancer
ChiCTR2500108745Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adebrelimab and vunakizumab in small cell lung cancer (SCLC), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: 6-month progression-free survival rate during maintenance period. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
adebrelimabvunakizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2500108745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108745.